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ABSTRACT
Over a 10-year period (January 1993 to October 2002), 101 relapsed or refractory non-Hodgkin lymphoma
patients were treated at our center with high-dose chemotherapy and autologous transplantation. The median
patient age was 54 years (range, 25-70 years). Thirty-two patients had indolent (low-grade), 42 had aggressive
(intermediate-grade), and 27 had very aggressive (high-grade) non-Hodgkin lymphoma. Thirty-six patients
had primary refractory disease, 20 had a chemoresistant relapse, 35 patients had a chemosensitive relapse, and
10 patients were “initial high risk” patients. The median number of prior chemotherapy regimens was 2 (range,
1-5). The preparative regimen (BEP) was bischloroethylnitrosourea (BCNU) 600 mg/m2, etoposide
2400 mg/m2, and Platinol (cisplatin) 200 mg/m2 given intravenously over 5 days. Within 3 weeks before
transplantation, 70 patients received involved-field radiotherapy (IFR) 20 Gy to sites of currently active (>2
cm) or prior bulky (>5 cm) disease. Most patients (n  93) received mobilized peripheral blood stem cells
(median CD34 cell dose, 6.7  106/kg). Median neutrophil (>500/L) and platelet (>20 000/L, untrans-
fused) recoveries were 11 days (range, 7-19 days) and 14 days (range, 7-36 days), respectively. At a median
follow-up of 41 months (range, 4 to 118 months) for survivors, Kaplan-Meier 5-year probabilities of overall
survival (OS) and disease-free survival (DFS) were 58.6% and 51.1%, respectively. Four patients (4%) died
within 30 days of stem cell infusion (1 pulmonary embolism, 2 septicemias with multiorgan failure, and 1
progressive lymphoma). Two patients (2%) developed interstitial pneumonitis most likely secondary to
high-dose BCNU. Three cases (3%) of secondary acute myelogenous leukemia occurred. On multivariate
analysis, age (<60 or >60 years), histologic grade (low versus intermediate or high), the use of IFR, and
chemotherapy response at baseline did not affect OS or DFS. Of 70 patients given IFR, 27 relapsed: 10 (37%)
within and 17 (63%) outside the radiation field. The use of IFR did not affect either OS or DFS, probably
because IFR was offered to patients with bulky or chemoresistant disease. BEP with or without IFR is a highly
effective and well-tolerated regimen in the relapsed/refractory lymphoma setting. It has low morbidity and
transplant-related mortality and a low incidence (3%) of posttransplantation malignancy.
© 2005 American Society for Blood and Marrow Transplantation
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1NTRODUCTION
Non-Hodgkin lymphomas (NHL) represent a class
f chemosensitive neoplasms for which approximately
0% to 50% of patients with intermediate- and high-
rade disease achieve disease-free survival at 4 to 5 years
fter conventional chemotherapy [1]. A randomized
tudy validated the superiority of high-dose chemother-
py (HDC) with autologous stem cell transplantation
ASCT) over conventional salvage chemotherapy in the
etting of chemosensitive disease relapse [2]. In patients
ith primary refractory NHL, the disease-free survival
DFS) after HDC and ASCT is approximately 30% to
5% [3]. Disease relapse, most often at sites of prior
nvolvement, accounts for most treatment failures after
DC and ASCT [4,5]. This ﬁnding has prompted an
nterest on the part of investigators in the use of in-
olved-ﬁeld radiotherapy (IFR) as an adjunct to HDC
nd ASCT to minimize the local relapse rate. Although
ultiple radiation-based and chemotherapy-alone con-
itioning regimens have been incorporated into the
ransplant setting, no randomized studies have demon-
trated the superiority of one regimen over any other
6,7]. Transplant-related complications, including pul-
onary toxicity and secondary myelodysplastic syn-
romes (MDS), also may account for morbidity and
ortality after ASCT [8,9]. We reported previously on
he promising results of our phase I to II multi-institu-
ional trial investigating a novel high-dose chemother-
py-alone conditioning regimen, BEP (bischloroethylni-
rosourea [BCNU], etoposide, and Platinol [cisplatin]),
n the relapsed and refractory lymphoma setting [10]. In
his report, we describe our single-institution phase II
xperience in 101 relapsed/refractoryNHLpatients sub-
equently undergoing ASCT with this BEP regimen
usually in conjunction with IFR) during a 10-year pe-
iod (1993-2002), with a special emphasis on the regi-
en efﬁcacy and low incidence of transplant-related
omplications.
ATIENTS AND METHODS
atients
Between January 1993 and October 2002, 101 pa-
ients with relapsed/refractory disease or high-risk NHL
atients were treated with HDC and ASCT. Patients
ere treated within the conﬁnes of protocols approved
y the Institutional Review Board at the University Hos-
itals of Cleveland, Comprehensive Cancer Center of
he Case Western Reserve University. Patients gave
ritten, informed consent to participate. Subjects were
ligible if they had primary refractory disease (failure to
chieve at least a partial remission after 2 cycles of front-
ine chemotherapy or failure to achieve a complete re-
ission after 6 cycles of front-line chemotherapy) or
elapsed disease. Patients with relapsed disease were fur-
her classiﬁed as having either a chemosensitive relapse 3
450% reduction in measurable disease after conven-
ional salvage chemotherapy) or a chemoresistant relapse
50% reduction in measurable disease after conven-
ional salvage chemotherapy). NHL patients also were
ligible if they had attained their ﬁrst complete or near-
omplete remission after induction chemotherapy but
ere deemed to be at high risk for a relapse according to
riteria described in the International Prognostic Index
coring system [11]. NHLwas classiﬁed according to the
orking Formulation [12] and the World Health Or-
anization classiﬁcation [13]. Cases of mantle cell lym-
homa were assigned to the low-grade NHL group for
tatistical analysis. Patients were required to have an
astern Cooperative Oncology Group performance sta-
us of 2, absence of active infection, and adequate
ardiac, pulmonary, hepatic and renal function. Speciﬁ-
ally, patients were eligible if their left ventricular ejec-
ion fraction was at least 40% on multiple-gated acqui-
ition scan, their corrected diffusing capacity of the lung
or carbon monoxide and forced expiratory volume in 1
econd were at least 60% of predicted, serum direct
ilirubin was 2.0 mg/dL, and calculated creatinine
learance was at least 60 mL/min.
reatment
Most patients received salvage chemotherapy
efore transplantation, most often a regimen based
n cisplatin, cytosine arabinoside, and dexametha-
one, with or without etoposide [14,15]. Before the
ransplantation, 70 patients also received IFR to
ites of currently active (tumor diameter exceeding
cm) or previous bulky (deﬁned as a tumor site
xceeding 5 cm in diameter at initial presentation)
isease. IFR was not administered unless at least
0% of all active and bulky disease could be treated.
reatment was administered in 2-Gy fractions once
aily for up to 10 treatments in the 14 days preced-
ng the initiation of the HDC preparative regimen.
ome of the earlier patients received harvested au-
ologous bone marrow mononuclear cells, whereas
ost of the patients treated after 1994 received
obilized peripheral blood stem cells. The regimen
ost commonly used to accomplish stem cell mo-
ilization was cyclophosphamide 4 g/m2 infused in-
ravenously over 6 hours and granulocyte colony-
timulating factor (ﬁlgrastim, Neupogen; Amgen,
housand Oaks, CA) 10 g/kg/d subcutaneously
16-18]. Twelve patients received etoposide in ad-
ition to cyclophosphamide, administered at 200
g/m2 intravenously over 3 hours daily for 3 days.
reparative Regimen and Stem Cell Infusion
High-dose therapy (schema outlined in Table 1)
omprised BCNU 200 mg/m2 in 500 mL of 5% dex-
rose water given intravenously over 2 hours daily for
days, etoposide 800 mg/m2 administered as a native
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BEP Regimen in Lymphoma Autografts
Brug intravenously during a 4-hour period via an in-
usion pump daily for 3 days [19], and cisplatin
0 mg/m2 in 250 mL of 3% saline infused intrave-
ously over a 3-hour period preceded by intravenous
urosemide and followed by mannitol daily for 5 con-
ecutive days. Cryopreserved autologous bone marrow
r blood stem cells were reinfused 72 hours after
ompletion of the preparative regimen.
upportive Care
All patients were treated in high-efﬁciency particu-
ate air–ﬁltered isolation rooms during the period of
ranulocytopenia. Patients who underwent transplanta-
ion after 1994 were treated with daily recombinant
ranulocyte colony-stimulating factor 5 g/kg or gran-
locyte-macrophage colony-stimulating factor (sar-
ramostim, Leukine; Berlex, Seattle, WA) 250 g/m2
ubcutaneously starting the day of transplantation and
ontinuing until an absolute neutrophil count of
500/L was reached. After transplantation, patients
eceived standard supportive care for the treatment of
eutropenic fevers with broad-spectrum antibacterial
rugs (usually a third-generation cephalosporin or an
xtended-spectrum penicillin combined with an amino-
lycoside), with the addition of amphotericin B or ﬂu-
onazole for persistent fevers beyond 72 to 96 hours.
cyclovir was administered at 250 mg/m2 intravenously
very 8 hours from the day of stem cell reinfusion until
eutrophil recovery. Gastrointestinal adverse effects,
ucositis, and esophagitis were managed according to
tandard supportive care practice guidelines. Addition-
lly, patients were treated with prednisone 2 mg/kg/d by
outh from day 7 until day 13 after transplantation,
ollowed by a rapid taper over the subsequent week to
inimize the development of interstitial pneumonitis
econdary to high-dose BCNU. Patients were transfused
ith irradiated blood products to maintain a platelet
ount 10 000/L and hemoglobin 10 g/dL. Toxic-
ties were graded according to the common toxicity cri-
eria of the National Cancer Institute.
tatistical Methods
Overall survival (OS) was measured from the date
able 1. High-Dose Chemotherapy Schema
Variable 7 6 
CNU 200 mg/m2 IV (600 mg/m2) X X
toposide 800 mg/m2 IV (2400 mg/m2) X X
isplatin 40 mg/m2 IV (200 mg/m2) X X X
est
tem cell infusion
rednisone 2 mg/kg/d PO
rednisone taper
V indicates intravenously; PO, by mouth.f transplantation to the date of death and was cen- r
B&MTored at the date of last follow-up for survivors. DFS
as measured from the date of transplantation to the
ate of death or relapse and was censored at the date
f last follow-up for survivors without relapse. The
robability of OS and DFS was estimated by the
aplan-Meier method [20]. The log-rank test was
sed to assess differences in outcome between/among
roups. Univariate analyses were performed with the
og-rank test. Factors potentially predictive of OS
ere entered into a multivariate analysis by using the
ox proportional hazards model [21]. The factors
ncluded in the Cox model were age, histologic grade,
se of IFR, and chemotherapy response at baseline.
ll tests were 2 sided, and P values 0.05 were con-
idered signiﬁcant.
ESULTS
atient Characteristics
Patient characteristics are outlined in Table 2. A
otal of 101 patients (68 men and 33 women) received
utografts during a 10-year period. Of these subjects,
2 had low-grade NHL (including 7 patients with
antle cell lymphoma), 42 had intermediate-grade
HL, and 27 had high-grade NHL (including 5 pa-
ients with Burkitt lymphoma). The median age was
4 years (range, 25-70 years), and 16 patients (16%)
ere older than 60 years. Forty-seven (46.5%) pa-
ients had bone marrow involvement at diagnosis. The
ean serum lactate dehydrogenase at the time of
ransplantation was 413 U/L (range, 112-2435 U/L).
hirty-six patients (35.6%) had primary refractory
isease, 35 patients (34.7%) had a chemosensitive re-
apse, 22 patients (19.8%) had a chemoresistant re-
apse, and 10 patients (9.9%) were patients with high-
isk disease who underwent transplantation in the ﬁrst
omplete or near-complete remission. The median
umber of chemotherapy regimens before transplan-
ation was 2 (range, 1-5). Seventy patients (69.3%)
eceived IFR (20 Gy) to sites of currently active or
reviously bulky disease, as deﬁned previously. Of the
0 patients who received IFR, 24 (34.2%) received
ediastinal radiation. Most patients (93/101; 92%)
Day
4 3 2, 1 0 7 to 13 14 to 20
X
X
X X
X
X
X
X5 eceived mobilized peripheral blood stem cells (me-
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1ian CD 34 cell dose, 6.7  106/kg; range, 1.7-22 
06/kg). Eight patients received unstimulated autolo-
ous bone marrow cells (median mononuclear cell
ose, 2.3  108/kg; range, 1.9-3  108/kg).
utcomes
At a median follow-up of 41 months for survivors
range, 4-118 months), the Kaplan-Meier 5-year
robability of DFS and OS for the entire group was
1.1% and 58.6%, respectively (Figures 1 and 2).
ables 3 and 4 (univariate analyses) show that neither
ge (60 years versus 60 years) nor the use of IFR
or lymphoma grade (low versus intermediate or
igh) affected OS or DFS; there was a trend, however,
oward a shorter DFS for patients with low-grade
HL (P  .204).
isease Status
When stratiﬁed according to disease responsive-
ess (primary refractory disease, chemoresistant re-
apse, chemosensitive relapse, or patients with high-
able 2. Patient Characteristics
Variable
otal
ale
emale
edian age, y (range)
ean LDH, U/L
istology
Low-grade NHL ( mantle cell)
Intermediate-grade NHL
High-grade NHL
edian no. prior chemotherapy regimens (range)
isease status at transplantation
Primary refractory
Chemosensitive relapse
Chemoresistant relapse
Primary high risk
DH indicates lactate dehydrogenase.
igure 1. Kaplan-Meier probability of disease-free survival for all
atients. t
6isk disease who underwent transplantation in ﬁrst
omplete remission), there was no signiﬁcant differ-
nce in the DFS or OS in each of these groups (Fig-
res 3 and 4). Of note, this regimen was very active in
he group of patients with primary refractory disease;
he 5-year DFS and OS were 54.1% and 63%, respec-
ively, comparable to those in patients with chemo-
ensitive relapsed disease. When the group of 10 high-
isk patients who underwent transplantation in ﬁrst
omplete remission was compared with the other 3
roups collectively, there was a statistically signiﬁcant
mprovement in OS and DFS; all 10 patients remain
live and disease free at a median follow-up of
8 months (P  .01).
istology
For NHL, OS for the 32 patients with low-grade
isease did not differ compared with that for the 69
ubjects with intermediate- or high-grade disease
62.5% versus 56.3%; P  .593), although there was a
ohort No-IFR Cohort All Patients
0 31 101
8 20 68
2 11 33
5-70) 50 (33-66) 54 (25-70)
4 419 413
7 15 32
5 7 42
8 9 27
-5) 2 (1-4) 2 (1-5)
9 7 36
2 13 35
7 3 20
2 8 10
igure 2. Kaplan-Meier probability of overall survival for all pa-IFR C
7
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BEP Regimen in Lymphoma Autografts
Brend toward a lower DFS in the low-grade compared
ith the intermediate-/high-grade group (36.6% ver-
us 57.9%; P  .204).
nvolved-Field Radiation
Seventy patients received IFR to sites that were
reviously bulky (5 cm) or currently active (2 cm)
mmediately before the chemotherapy preparative
egimen was initiated. For these patients, there was no
igniﬁcant difference in OS (54% versus 72.3%; P 
478) or DFS (49.7% versus 52.9%; P  .56) when
ompared with the 31 patients who did not receive
FR (Figures 5 and 6). Twenty-seven of the 70 pa-
ients treated with IFR relapsed: 10 (37%) relapses
ccurred within the ﬁeld of radiation, and 17 (63%)
ere outside it.
oxicities
All patients developed neutropenia and thrombo-
ytopenia but engrafted and recovered peripheral
able 4. Kaplan-Meier Estimation of Overall Survival Function for V
Factor n Survival at 1 y S
ll patients 101 83
ge (y)
<60 85 83.4
>60 16 81.3
FR
No 31 83.5
Yes 70 82.9
rade
IM/H 69 80.8
Low 32 87.5
hemotherapy response
Primary refractory 36 86.1
Chemoresistant relapse 20 70
Primary high risk 10 100
Chemosensitive relapse 35 82.7
able 3. Kaplan-Meier Estimation of Disease-Free Survival Function f
Factor n Survival at 1 y
ll patients 101 74.9
ge (y)
<60 85 73.8
>60 16 81.3
FR
No 31 72.8
Yes 70 75.7
rade
IM/H 69 74.9
Low 32 75
esponse to chemotherapy
Primary refractory 36 77.8
Chemoresistant relapse 20 60
Primary high risk 10 100
Chemosensitive relapse 35 73.7
M/H indicates intermediate/high.M/H indicates intermediate/high.
B&MTlood counts. Median neutrophil (500/L) and
latelet (20 000/L, untransfused) recoveries were
1 days (range, 7-19 days) and 14 days (range, 7-36
ays), respectively. For the 70 patients who received
FR, the median neutrophil recovery was 10 days
range, 7-19 days), compared with 11 days (range,
-19 days) for the subjects who did not receive IFR.
latelet recovery was also similar in the 2 cohorts: 14
ays (range, 8-36 days) in the IFR group versus 15
ays (range, 7-26 days) in the absence of IFR. Six (6%)
f the 101 patients developed acute renal failure after
DC. Four of these cases occurred in the context of
epticemia and multisystem organ failure and hypo-
ension; in 2 cases, no other underlying cause of the
enal failure was identiﬁed (possibly secondary to
igh-dose cisplatin). Four patients recovered renal
unction after hemodialysis support, whereas 2 pa-
ients died as a result of septicemia and multisystem
rgan failure.
Four patients died within 30 days of stem cell rein-
roups
l at 3 y Survival at 5 y Survival at 7 y P Value
7.8 58.6 50.3
7.2 60.1 51.5 .837
3.1 56.9
2.3 72.3 .478
5.9 54 54
4.1 56.3 56.3 .593
5.7 62.5
1.8 63 63
5.1 47.3 47.3 .116
0 100
0.8 49.1 24.6
ous Groups
al at 3 y Survival at 5 y Survival at 7 y P Value
4.6 51.1 44.8
2.3 52.3 45.3 .845
5.7 49.2
2.9 52.9 .56
4.2 49.7 41.3
0.4 57.9 52.6 .204
2.7 36.6
4.1 54.1 54.1
6.8 39 39 .062
0 100
8.4 43 26.9arious G
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1usion (transplant-related mortality of 3.5%); 2 of these
atients received IFR before the transplantation. One
atient developed a fatal pulmonary embolus, 2 subjects
ied as a result of septicemia and multisystem organ
ailure (1 with herpes simplex virus-1 fulminant hepatic
ecrosis and sepsis), and 1 patient died of progressive
ymphoma. Grade 3 or 4 mucositis was observed in 9
29%) of 31 patients not receiving IFR and in 40 (57.1%)
f 70 patients receiving IFR (P .009). Nine episodes of
ew-onset atrial ﬁbrillation were observed during the
ourse of the transplantation, all of which occurred in the
ontext of electrolyte imbalance (hypokalemia, hypo-
agnesemia, or their combination), despite aggressive
aily monitoring of serum electrolytes. Culture-positive
loodstream infections were noted in 9 (29%; 8 bacte-
emias and 1 fungemia) of the 31 patients who did not
eceive IFR and in 13 (18.6%; 10 bacteremias and 3
ungemias) of the 70 patients treated with IFR (P .24).
A low incidence of interstitial pneumonitis was noted
igure 3. Kaplan-Meier probability of disease-free survival accord-
ng to disease status: primary refractory disease (n36), chemore-
istant relapse (n20), chemosensitive relapse (n35), and high-
isk ﬁrst complete remission (n10).
igure 4. Kaplan-Meier probability of overall survival according to
isease status: primary refractory disease (n36), chemoresistant
elapse (n20), chemosensitive relapse (n35), and high-risk ﬁrstuomplete remission (n10).
82/101 patients; 2%). Neither of these patients had re-
eived radiation therapy to the mediastinum. The diag-
osis of interstitial pneumonitis was made clinically by
xclusion of other causes of pulmonary pathology. These
atients presented with dyspnea and hypoxemia within
20 days of transplantation and had radiologic evidence
f interstitial or perihilar inﬁltrates. Infectious etiologies
nd pulmonary embolism were excluded by broncho-
copic alveolar lavage and spiral computed tomography
r ventilation/perfusion scanning, respectively. Both pa-
ients had a restrictive pattern on pulmonary function
esting, and one had an open lung biopsy that revealed a
attern of diffuse interstitial ﬁbrosis. Both subjects were
reated with corticosteroids and improved; one, how-
ver, remains dependent on supplemental oxygen at 40
onths after transplantation.
econdary Malignancies
At the time of last follow-up, no secondary solid
umors had occurred in any patient in this series.
hree cases of secondary MDS/acute myelogenous
igure 5. Kaplan-Meier probability of disease-free survival accord-
ng to use of IFR (n70) versus no IFR (n31).
igure 6. Kaplan-Meier probability of overall survival according to
se of IFR (n70) versus no IFR (n31).
l
t
w
w
p
t
o
q
r
a
u
l
o
o
f
m
c
S
t
i
a
m
p
a
p
o
N
h
a
g
D
m
t
t
r
d
h
u
c
f
K
a
s
v
a
m
v
i
a
W
l
w
a
p
c
A
m
N
a
a
f
p
D
w
p
s
p
K
A
r
r
h
3
s
p
r
p
a
p
p
t
r
w
p
a
f
c
d
h
m
d
.
p
m
(
d
p
t
w
d
c
t
m
m
t
g
BEP Regimen in Lymphoma Autografts
Beukemia (AML) were noted. The ﬁrst patient ini-
ially had stage IIA lymphoblastic lymphoma and
as treated according to the Coleman regimen [22]
ith cyclophosphamide, doxorubicin, vincristine,
rednisone, l-asparginase, methotrexate, and intra-
hecal cytosine arabinoside. She also received 20 Gy
f IFR to the neck and mediastinum and subse-
uently underwent an autograft in ﬁrst complete
emission. Ten months later, she developed second-
ry AML (trisomy 7, trisomy 10, and t[5:13]). She
nderwent a myeloablative peripheral blood sib-
ing-matched allograft but died 2 months later sec-
ndary to hepatic veno-occlusive disease. The sec-
nd patient had an initial diagnosis of stage IV
ollicular small cleaved NHL, received 3 prior che-
otherapy regimens, and was given IFR to the right
ervical and periaortic nodes before transplantation.
he developed secondary AML 55 months after
ransplantation. She received a reduced-condition-
ng sibling-matched allogeneic stem-cell transplant
nd remains in complete hematologic remission 12
onths after the second transplantation. The third
atient had long-standing low-grade NHL; 9 years
fter diagnosis, she underwent an autograft and ex-
osure to numerous cytotoxic regimens. She devel-
ped secondary AML 4 years after autografting for
HL, was induced into a complete remission with
igh-dose cytarabine, and remains well 19 months
fter a reduced-conditioning sibling-matched allo-
eneic peripheral blood stem cell transplantation.
ISCUSSION
We previously reported our phase I and II
ulti-institutional pilot data with the BEP chemo-
herapy conditioning regimen in relapsed/refrac-
ory NHL and Hodgkin disease [10]. In the current
eport, we present our single-institution phase II
ata on 101 subsequent relapsed, refractory, or
igh-risk NHL or Hodgkin disease patients who
nderwent ASCT with the BEP regimen, usually in
onjunction with IFR, as described. At a median
ollow-up of 41 months for survivors, the 5-year
aplan-Meier probabilities of DFS and OS (51.1%
nd 58.6%, respectively) compare favorably with
everal of the larger reports in the literature with a
ariety of total body irradiation(TBI)– containing
nd non–TBI-containing regimens [23-28]. With a
ultivariate analysis, factors such as age (60 years
ersus 60 years), grade of lymphoma (low versus
ntermediate or high), use of IFR, and chemother-
py response at baseline did not affect OS or DFS.
e did note a lower DFS trend for 32 patients with
ow-grade NHL (36.6% versus 57.9%; P  .204)
hen compared with 69 patients with intermedi-
te-/high-grade NHL; this ﬁnding could be ex- B
B&MTlained, in part, by the natural history of an in-
reased tendency of low-grade NHL to relapse.
dditionally, for statistical analysis, 7 patients with
antle cell NHL were included in the low-grade
HL group; at last follow-up, all 7 had relapsed,
nd 5 had died.
Of note, contrary to many reports in the liter-
ture, disease chemosensitivity did not seem to af-
ect DFS and OS in our study. For our group of 36
atients with primary refractory disease, the 5-year
FS and OS were 54.1% and 63%, respectively,
hich did not differ signiﬁcantly compared with
atients who had chemosensitive relapse. This re-
ult compares favorably to data generated from 85
atients with primary refractory NHL reported by
ewalramani et al. [25]. Further, data from the
utologous Blood and Marrow Transplant Registry
eport [3] describe 184 patients with NHL primary
efractory disease who underwent autografts and
ad 5-year probabilities of DFS and OS of only
1% and 37%, respectively. Although our regimen
eems to be particularly promising in this patient
opulation, the results, similarly, are based on a
etrospective analysis and need to be reproduced
rospectively in a larger cohort of patients.
Our conditioning regimen was well tolerated and
ssociated with a surprisingly low incidence of interstitial
neumonitis (2/101; 2%). BCNU pulmonary toxicity,
otentially related to the inhibition of glutathione reduc-
ase in alveolar macrophages [29], seems to be dose
elated, with a 28% incidence at 600 mg/m2 compared
ith 4% at 450 mg/m2 [30]. Jones et al. [31] reported
harmacokinetic data on 38 breast cancer and NHL
utotransplant recipients given BCNU 600 mg/m2 (in-
used in 1 day), cyclophosphamide 1875 mg/m2, and
isplatin 165 mg/m2. Twenty (53%) of the 38 patients
eveloped pulmonary injury. Twelve affected subjects
ad BCNU area under the curve values 600 g/mL/
in, whereas only 2 (11%) of 18 patients who did not
evelop lung injury had values above this cutoff (P 
03); eg, organ dysfunction arose in 12 (86%) of 14
atients with a BCNU area under the curve 600 g/
L/min. Although we infused an identical BCNU dose
600 mg/m2), this agent was administered in divided
oses over 3 days; it is reasonable to speculate that our
atients had lower peak BCNU concentrations. Addi-
ionally, given the data for the beneﬁt of early treatment
ith corticosteroids to attenuate the chemotherapy-in-
uced decline in the diffusing capacity of the lung for
arbon monoxide [32], we routinely treated all our pa-
ients with prophylactic corticosteroids (prednisone 2
g/kg) from days 7 through 14. This approach, in part,
ay account for the relatively low incidence of intersti-
ial pneumonitis we observed. Of interest, other investi-
ators who substituted high-dose lomustine in place of
CNU in combination with cyclophosphamide and eto-
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2oside in HDC regimens reported a persistently high
ncidence (63%) of interstitial pneumonitis [33].
The incidence of secondary MDS/AML in this
tudy was low (3/101 patients; 3%). Multiple studies in
he literature have addressed the issue of posttransplan-
ation MDS/AML in NHL patients and have described
6% to 12% incidence rate. Some of the predictive
retransplantation and transplantation-related risk fac-
ors include older patient age, a lower dose of infused
ematopoietic progenitors, prior ﬂudarabine or alkylator
hemotherapy, stem cell mobilization with an etoposide-
ontaining regimen, prior radiotherapy, an increased in-
erval from diagnosis to transplantation, lower platelet
ount at or before transplantation, and lymphomatous
one marrow involvement [34-39]. In a recently pub-
ished Autologous Blood and Marrow Transplant Reg-
stry report on 56 secondary MDS/AML patients within
cohort of 2739 NHL/Hodgkin disease patients receiv-
ng autotransplants, a TBI dose of 13.2 Gy signiﬁcantly
ncreased leukemia risks (relative risk, 4.6; P  .03),
hereas a 12-Gy dose did not seem to increase the
econdary leukemia risk (relative risk, 1.3, P .48) above
hat seen with non-TBI regimens [12]. Our reported
ncidence of secondary MDS/AML is lower than that
bserved in other published studies, for unclear reasons.
The role and beneﬁt of IFR in the transplant
etting is complex [40]. although some studies have
emonstrated improved DFS in patients with bulky
isease or improved local control of irradiated sites
28,41,42], no study has convincingly demonstrated
mproved OS in irradiated patients. Additionally, mul-
iple investigators caution about increases in hemato-
ogic toxicity [43], pulmonary morbidity [44], trans-
lant-related MDS/AML, and transplant-related
ortality [45] in patients receiving IFR. Seventy pa-
ients on our protocol were treated with IFR to pre-
iously bulky or currently active disease sites. IFR did
ot seem to delay time to hematopoietic recovery after
ransplantation: the median time to neutrophil recov-
ry500/L was 10 and 11 days and the median time
o platelet recovery 20 000/L (untransfused) was
4 and 15 days when comparing irradiated versus
onirradiated patients, respectively. Two patients de-
eloped interstitial pneumonitis in our study; neither
f these had received prior mediastinal irradiation.
wo of 3 cases of secondary AML occurred in patients
ho had received prior IFR. Of the 70 patients treated
ith IFR, 27 relapsed: 10 (37%) within and 17 (63%)
utside the radiation ﬁeld. In our study, the 5-year
FS for the 70 patients who received IFR was no
ifferent from that for the 31 patients who did not
eceive radiation (49.7% versus 52.9%; P  .56). Of
he 70 patients who received IFR, 41% had primary
efractory disease and 24% had a chemoresistant re-
apse, compared with 22% with primary refractory
isease and 10% with chemoresistant relapse among
he 31 patients who did not receive IFR. Although
0hese comparisons did not reach statistical signiﬁcance
P  .10; data not shown), there was undoubtedly a
rend toward a higher proportion of patients with
rimary refractory disease and chemoresistant relapses
n our IFR cohort. Hence, the apparent lack of beneﬁt
f IFR must be interpreted with caution in light of this
nherent selection bias of offering IFR to patients with
ulky or chemoresistant disease.
This single-institution report of long-term fol-
ow-up with the BEP preparative regimen with or
ithout IFR followed by autologous transplantation
or relapsed or refractory NHL and Hodgkin disease
emonstrates the treatment to be highly effective and
ell tolerated, with a low incidence of interstitial
neumonitis compared with other high-dose BCNU
egimens. Further, this approach seems to be associ-
ted with a low incidence of secondary MDS/AML
nd seems to be particularly promising in the setting
f primary refractory disease.
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